0001062993-24-003202.txt : 20240214 0001062993-24-003202.hdr.sgml : 20240214 20240214184324 ACCESSION NUMBER: 0001062993-24-003202 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240212 FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dorling Janet CENTRAL INDEX KEY: 0001738144 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36500 FILM NUMBER: 24641321 MAIL ADDRESS: STREET 1: C/O ACHAOGEN, INC. STREET 2: 1 TOWER PLACE, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc. CENTRAL INDEX KEY: 0001042074 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943103561 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-293-8800 MAIL ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX, INC. DATE OF NAME CHANGE: 20090721 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX INC DATE OF NAME CHANGE: 19970710 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-02-12 0001042074 CymaBay Therapeutics, Inc. CBAY 0001738144 Dorling Janet C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110 NEWARK CA 94560 1 0 0 0 1 Common Stock 2024-02-12 4 M 0 6000 4.63 A 6000 D Common Stock 2024-02-12 4 S 0 6000 31.9748 D 0 D Employee Stock Option (right to buy) 4.63 2024-02-12 4 M 0 6000 0 D 2031-04-04 Common Stock 6000 55000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on August 9, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.93 to $32.00, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option grant vests as to 1/36 of the underlying shares monthly from April 5, 2021. /s/ Paul Quinlan, as attorney-in-fact for Janet Dorling 2024-02-14